NCT03349242 is a clinical trial in Retinitis Pigmentosa, sponsored by MeiraGTx UK II Ltd.

Who is sponsoring NCT03349242?

NCT03349242 is sponsored by MeiraGTx UK II Ltd.

What condition does NCT03349242 study?

NCT03349242 studies Retinitis Pigmentosa.

Is NCT03349242 still recruiting?

NCT03349242 is currently completed. Last updated 20 June 2024.

Last reviewed 2024-06-20 · How we verify

NCT03349242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

Completed Last updated 20 June 2024

What this trial tests

trial in Retinitis Pigmentosa in 140 participants. Completed in 19 April 2024.

Timeline

19 December 2017

Primary endpoint
19 April 2024

19 April 2024

Quick facts

Lead sponsor	MeiraGTx UK II Ltd
Status	Completed
Study type	OBSERVATIONAL
Enrollment	140
Start date	19 December 2017
Primary completion	19 April 2024
Estimated completion	19 April 2024
Sites	8 locations across United Kingdom, Canada, United States

Conditions studied

Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →

Sponsor

MeiraGTx UK II Ltd — full company profile →

Who can join

5 and older, any sex, with Retinitis Pigmentosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically and genetically heterogeneous group of disorders in which there is progressive loss of rod and later cone photoreceptor function leading to severe visual impairment. RP usually occurs as an isolated retinal disorder, but it may also be seen in association with systemic abnormalities.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease.
Ong T, Pennesi ME, Birch DG, Lam BL, et al · · 2019 · cited 46× · PMID 30617669 · DOI 10.1007/s11095-018-2564-5
Molecular Strategies for RPGR Gene Therapy.
Cehajic Kapetanovic J, McClements ME, Martinez-Fernandez de la Camara C, MacLaren RE. · · 2019 · cited 33× · PMID 31487940 · DOI 10.3390/genes10090674
X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical Aspects.
Mansouri V. · · 2023 · cited 18× · PMID 36346573 · DOI 10.1007/s40123-022-00602-y
Impact of Reference Center Choice on Adaptive Optics Imaging Cone Mosaic Analysis.
Roshandel D, Sampson DM, Mackey DA, Chen FK. · · 2022 · cited 8× · PMID 35446344 · DOI 10.1167/iovs.63.4.12
Pearls and Pitfalls of Adaptive Optics Ophthalmoscopy in Inherited Retinal Diseases.
Ashourizadeh H, Fakhri M, Hassanpour K, Masoudi A, et al · · 2023 · cited 4× · PMID 37510157 · DOI 10.3390/diagnostics13142413
Health state utilities associated with X-linked retinitis pigmentosa (XLRP).
Matza LS, Li N, Stewart KD, Hashim M, et al · · 2025 · cited 2× · PMID 40095340 · DOI 10.1007/s10198-025-01761-y
Advances in RPGR gene therapy for X‑linked retinitis pigmentosa: From preclinical insights to clinical application (Review).
Long Y, Qi J, Zhang W, Qin H, et al · · 2026 · PMID 41480687 · DOI 10.3892/ijmm.2025.5723

Verify or expand the search:

Other recruiting trials for Retinitis Pigmentosa

Currently open trials in the same condition.

NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting

Other MeiraGTx UK II Ltd trials

Trials by the same sponsor.

NCT03758404 — Gene Therapy for Achromatopsia (CNGA3) · Phase 1, PHASE2 · completed
NCT04043104 — A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects · Phase 1 · completed
NCT03252847 — Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) · Phase 1, PHASE2 · completed
NCT03278873 — Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 · terminated
NCT03001310 — Gene Therapy for Achromatopsia (CNGB3) · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03349242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MeiraGTx UK II Ltd
Last refreshed: 20 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03349242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing